HMGCR and chronic kidney disease: Randomized controlled trials with prespecified primary renal outcomes failed to demonstrate a beneficial effect of HMG-CoA reductase inhibitors (statins) on kidney function [39,40], but those trials had limited statistical power and were restricted to patients already diagnosed with chronic kidney disease (CKD).